Menovo(SH:603538) Zheng Quan Zhi Xing·2025-08-26 16:23Summary of Key Points Core Viewpoint Ningbo Meinuo Pharmaceutical Co., Ltd. has provided a special report on the management and actual use of raised funds for the first half of 2025, detailing the amount raised, its allocation, and the management of these funds in compliance with regulatory requirements. Group 1: Fundraising Overview - The total amount raised through the issuance of convertible bonds was RMB 512,697,629.67, with all funds received by January 20, 2021 [1] - As of June 30, 2025, the net amount of raised funds was RMB 512,697,629.67, with RMB 120,013,509.22 allocated to supplement working capital [1][2] - The company earned RMB 2,447,966.77 in interest income from deposits, while RMB 2,018,894,525.00 was temporarily idle in financial products [1][3] Group 2: Fund Usage and Management - The company has implemented a dedicated account storage system for raised funds, ensuring compliance with relevant laws and regulations [1] - As of June 30, 2025, the total balance in dedicated accounts was RMB 20,183,440.32, with specific allocations for high-end formulation projects and raw material projects [1][2] - The high-end formulation project is expected to be completed by July 2025, with ongoing construction and planning [1][3] Group 3: Cash Management of Idle Funds - The company has approved the use of idle raised funds for cash management, with a maximum daily balance of RMB 25,000,000 allowed for investment in liquid and capital-preserving products [2] - As of June 30, 2025, the total amount used for cash management was RMB 29,000,000, generating a return of RMB 390,400 [2][3] - The company has not experienced any significant changes in the feasibility of its projects or the need to temporarily supplement working capital with idle funds [2][3]